However, since sorafenib targets multiple tyrosine-kinase receptors, it can cause a wide range of side effects, especially cardiovascular toxicity which is well known in patients with renal cell cancer and lung cancer who have been receiving it for a longer period. This evidence concerns the gene NTRK1 and renal cell adenocarcinoma.